GILD – gilead sciences, inc. (US:NASDAQ)

News

Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at UBS Group AG from $70.00 to $96.00. They now have a "neutral" rating on the stock.
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Mizuho from $90.00 to $100.00. They now have an "outperform" rating on the stock.
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Daiwa America to a "hold" rating.
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study [Yahoo! Finance]
How Gilead Is Driving Global Health Equity And Innovation [Forbes]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com